CD8A and neoplasm: Together, these data indicate that the treatment efficacy of tiragolumab plus atezolizumab combination was selectively albeit counterintuitively associated with TAMs and tumour Treg cells, in addition to typical correlates of checkpoint inhibitor responsiveness such as CD8+ effector T cells and PD-L1 expression.